Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Comparing individual angiotensin-converting enzyme inhibitors with losartan in the risk of hospitalization for pneumonia and related mortality: a nationwide cohort study

Chang, Chia-Hsuina,b,c; Lin, Jou-Weic,d; Ruan, Sheng-Yuana,b,c; Lee, Yen-Chieha,e; Wu, Li-Chiua; Lin, Min-Shunge; Lai, Mei-Shua

doi: 10.1097/HJH.0000000000000438
ORIGINAL PAPERS: Therapeutic aspects

Background: Angiotensin-converting enzyme (ACE) inhibitors might decrease the risk of pneumonia, but head-to-head comparisons with angiotensin receptor blockers (ARBs) were seldom made. The objective of this study was to evaluate incidence of pneumonia and mortality for different ACE inhibitors as compared to losartan, an ARB that has similar indications.

Methods: Adult patients aged more than 20 years who initiated ACE inhibitors and losartan between 1 January 2004 and 31 December 2009 were identified from Taiwan's National Health Insurance Database. The outcomes of interest were hospitalization for pneumonia and pneumonia-related mortality. Participants were followed from treatment initiation to the earliest of outcome occurrence, death or disenrollment, treatment discontinuation, switching to other ACE inhibitors or ARBs, or study termination (31 December 31 2010). Proportional-hazards regression model was used to calculate the hazard ratios and their 95% confidence intervals (CIs), adjusted on baseline characteristics.

Results: A total of 1 192 082 ACE inhibitors and 175 668 losartan initiators were included. The risk of hospitalization for pneumonia was significantly higher for captopril (hazard ratio 1.94, 95% CI 1.82–2.07), enalapril (hazard ratio 1.14, 95% CI 1.07–1.22), fosinopril (hazard ratio 1.11, 95% CI 1.02–1.21), perindopril (hazard ratio 1.14, 95% CI 1.04–1.25), and ramipril (hazard ratio 1.11, 95% CI 1.02–1.22), as compared with losartan. Captopril was associated with a significantly increased risk of pneumonia mortality (hazard ratio 2.43, 95% CI 1.79–3.31).

Conclusions: Treatment with ACE inhibitors is not associated with a lower risk of pneumonia incidence and mortality as compared with losartan.

Supplemental Digital Content is available in the text

aInstitute of Preventive Medicine, College of Public Health, National Taiwan University

bDepartment of Internal Medicine, National Taiwan University Hospital

cDepartment of Medicine, College of Medicine, National Taiwan University

dCardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, Dou-Liou City, Yun-Lin County

eDepartment of Family Medicine, Cathay General Hospital, Taipei, Taiwan

Correspondence to Dr Min-Shung Lin, Department of Family Medicine, Cathay General Hospital, 280 Renai Road, Section 4, Taipei, Taiwan Tel: +886 922861953; fax: +886 55373257; e-mail: andrewjovilin@gmail.com

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ATC, anatomical therapeutic chemical; CI, confidence interval; COX-2, cyclooxygenase-2; DDD, defined daily doses; DPP4, dipeptidyl peptidase-4; ICD, International Classification of Diseases; NHI, National Health Insurance; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; TRACE, Trandolapril Cardiac Evaluation

Received 28 April, 2014

Revised 29 September, 2014

Accepted 29 September, 2014

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.